



NCCP EXECUTIVE MANAGEMENT TEAM MEETING

I	Date:	Monday 13 th February 2023 @ 9am via MS teams	
I	Present:	R. Ó Laoide (Chair), P. Cafferty, T. Hanan, A. Hill, M. Keane, F. Murphy	(NSS)
,	Apologies:	C. Faul, T. McCarthy	
I	nvited:	AM DeFrein, H. Burns, M. Cox, A. Deane, C. Mellett, E. O'Toole, T. Flatte	ery
A. PR	ESENTATIO	DNS	
A1		– Cancer Drug Management Programme (AM. Defrein)	
	-	ate on the Cancer Drug Management programme was provided by	
	-	arie Defrein, Chief Pharmacist. The progress on the programme was	
		ed by members.	
A2	Draft G		
		Breast Radiation Oncology	
	2)	Prostate post-treatment surveillance	
		ne documents were discussed. The work of E. O'Toole and her team was	
		nded by members.	
	1)	The Breast Radiation Oncology guideline was endorsed by members.	
	Action:		
		The data section of the Prostate post-treatment surveillance guideline to	E. O'Toole
	_,	be amended to reflect the level of evidence in relation to follow up.	
		Document to be circulated to Guidelines group and discussed at next EMT	
		meeting for review and sign off	
B. MI		MATTERS ARISING	
B1		s of the previous meeting	
	The min	utes of the EMT meeting held on 9 th January 2023 were agreed.	
B2	Matters	Arising	
	1.	Risk Register	
		 This will be discussed at EMT meeting in March 	
C. DIRE	CTOR's IT	EMS	
C1	•	RHAs – work is ongoing within HSE	
	•	Accreditation – work is underway at EU level to gather information on	
		Irish cancer centres	
	•	Genetics & Genomics – strategy was launched in December 2022.	
		Workshops ongoing.	
	•	JCH – thanks to all for contributions which assisted in preparation	

D. STANDING ITEMS				
D1	Risk Register will be discussed at next meeting			
E1	Cancer Screening (F Murphy)			
	Noted that NSS received a small allocation of funds from NSP 2023			
E2	Evidence and Quality Hub (F Bonas/E. O'Toole)			

		1
	• E. O'Toole presented two draft guidelines (Breast Radiation Oncology and Prostate post-treatment surveillance) for discussion (as above)	
E3	Cancer Intelligence (M. Cox)	1
	KPI report was circulated in advance of meeting	
	 Some improvement in KPIs although resilience in the system remains a 	
	challenge.	
	Mitigation measures are in place for medical oncology services which	
	should help to improve timeliness of treatment in those hospitals experiencing particular challenges.	
	experiencing particular chanenges.	
E4	Public Health, Community Oncology and Prevention/Early Detection (H. Burns)	
	Covid Update – hospital case numbers are decreasing.	
	Influenza activity is also decreasing	
	• A webinar was held on 2 nd February for World Cancer Day (4 th February	
	2023). 195 people attended.	
	• E-learning modules on modifiable cancer risk were launched on 2nd	
	 February to target health and social care professionals The National Skin Cancer Prevention Plan will be launched soon – date to 	
	 The National Skin Cancer Prevention Plan will be launched soon – date to be confirmed 	
	 Upcoming social media activity will focus on Bowel Cancer Awareness 	
	month (March)	
	Action: Feedback to EMT on numbers of schools visited as part of the joint	H. Burns
	initiative with Marie Keating Foundation regarding cancer prevention.	
E5	Cancer Nursing (T Hanan/C. Osborne)	
	NCCP will be working with HSE communications to profile the work of the	
	Acute Oncology Nursing services in upcoming media articles.	
E6	Surgical Programme (A. Hill)	
LO	Access to theatres for surgery for cancer patients continues to be	
	prioritised	
	Action: Discuss update on surgical centralisation at future meeting	R. Ó Laoide / P. Cafferty
E7	Radiation Oncology (F. Bonas)	
	NCCP are participating in the national review of radiation therapists which	
	commenced in November 2022	
	• The Proton Group has been refreshed, new TOR agreed.	
	Action: Proton group update will be shared at next EMT meeting.	F. Bonas
E8	Systemic Therapy Programme [Medical Oncology/Haemato-oncology]	F. DUIIdS
20	(P. Heckmann/M Keane)	
	Systemic Therapy Programme	
	Service planning discussions still on-going.	
	A survey on haemato-oncology infrastructure is commencing based on the	
	NCCP Service Specification for Haemato-Oncology Services	
	HSE estates prioritisation in 2023 will be available shortly. This would include daywards and ACUs	
	daywards and ACUs.	
	There was discussion of the drug approval process, particularly in relation to timelines for company submission of HTAs and associated assocs to first line	
	timelines for company submission of HTAs and associated access to first line	
	treatment for patients. Needs to be considered for future IPHA agreements. Action: NCCP will raise IPHA Agreement and cancer drug process with the DoH	
	CPU	

	Molecular				
	• Support documentation for BRCA testing in prostate – predictive for drug use				
	is being finalised.				
	Roche Field Safety Notice (FSN) re SP142 is on-going				
E9	National Cancer Information System (NCIS) – P. Heckmann				
	Roll-out is continuing				
E10	Cancer Networks (F Bonas)				
	Network meetings are scheduled				
F	FOR INFORMATION				
	n/a				
G	AOB				
	n/a				
DATE O	DATE OF NEXT MEETING				
Monday 13 th March 2023 @ 10.30am					